What Is It about? {#sec1_1}
=================

Hypernatremic dehydration in term neonates is classically associated with inadequate fluid intake, particularly in breastfed infants. Although the literature proposes a maximum rate of serum sodium (SNa) reduction, there is no consensus about proper rehydration strategies in hypernatremic neonates. Both the degree of hypernatremia and the rate of SNa drop during treatment are key players in the development of serious adverse effects. We highlight the importance of conducting well-designed studies in order to elucidate remaining questions.

Introduction {#sec1_2}
============

Hypernatremic dehydration (serum sodium, SNa, ≥150 mmol/L \[[@B1]\]) in term neonates is classically associated with inadequate fluid intake, particularly due to insufficient lactation. The main predisposing factors include problems with maternal breast milk synthesis, difficulty with breast milk removal, and low daily breast milk intake \[[@B2]\]. Excessive weight loss, beyond 10% of birth weight, occurs in approximately 15% of exclusively breastfed infants \[[@B3]\] and approximately one third of them will be hypernatremic \[[@B4]\]. Diagnosis may be challenging because neonates have less pronounced clinical signs of dehydration \[[@B4]\] and excessive weight loss is not a mandatory finding \[[@B5]\]. The usual clinical presentation includes jaundice, hyperthermia, poor oral intake, low urine output, and lethargy, which are all unspecific signs for a great variety of diseases in the neonatal period \[[@B1], [@B6], [@B7], [@B8]\].

The incidence of hypernatremic dehydration is difficult to define. Ergenekon et al. \[[@B9]\] reported neonatal hypernatremic dehydration in 1% of all deliveries, while Bolat et al. \[[@B10]\] described it as being responsible for 1.8% of all neonatal admissions. This relatively common condition raises concern due to its potential of causing significant morbidity. Seizures \[[@B6], [@B11]\], acute renal injury \[[@B12]\], cerebral thrombosis, and hemorrhage \[[@B4]\] are among the most significant and potentially deleterious complications.

Besides the complications of the condition itself, reestablishment of plasma tonicity may also lead to serious damage if not done properly. The use of hypotonic fluids is appropriate to dilute the SNa, but cerebral edema may develop when it happens in an untimely manner. Although the literature describes that the maximum rate of SNa reduction should not surpass 0.5-1 mEq/L/h \[[@B13], [@B14]\], there is no consensus about proper rehydration strategies in hypernatremic neonates. There are no guidelines as to which extent hypernatremic dehydration may be corrected exclusively by increasing oral feeds, when parenteral fluids are indicated and which parenteral solution is appropriate to avoid excessive SNa correction. A review by Moritz et al. \[[@B14]\], for example, recommends using 0.2% saline in 5% dextrose in water for hypernatremia due to inadequate feeding, without specifying according to the degree of hypernatremia and acknowledging that there is no definitive documentation on the optimal rate of SNa reduction. The present systematic review aims at clarifying some of the issues regarding the correction of hypernatremic dehydration, particularly caused by insufficient lactation, in term neonates and the main outcomes of the treatment.

Methods {#sec1_3}
=======

In order to examine the best strategy of treatment for hypernatremia in neonates, we performed a systematic literature review, seeking studies describing which treatment was used, according to the method proposed by The Cochrane Collaboration \[[@B15]\] and the PRISMA guidelines \[[@B16]\]. This systematic review is registered at PROSPERO (registration number: CRD42016034119).

Searching {#sec2_1}
---------

The search was performed on the following databases: Clinical Trials, MEDLINE/PubMed, EMBASE, LILACS, and the Cochrane Library. The search was limited to studies published until January 31st, 2016.

The search strategy used at EMBASE was: ("term infant" OR "neonate"/exp OR "neonate" OR "newborn"/exp OR "newborn") AND ("hypernatraemia"/exp OR "hypernatraemia" OR "hypernatremic dehydration"). For the other databases, the search strategy was: (\["neonate"\] OR \["newborn"\] OR \["term infant"\] AND \["hypernatremia"\]) OR "hypernatremic dehydration". Ongoing studies were identified through searches of Clinical [Trials.gov](http://www.Trials.gov).

Study Selection and Characteristics {#sec2_2}
-----------------------------------

The title and abstracts of studies identified by the search were screened for potential relevance. The full text of all potentially relevant studies was reviewed to determine if they fulfilled the eligibility criteria. Studies were included if: (1) it was a randomized controlled trial (RCT); (2) the study included term neonates treated for hypernatremic dehydration; (3) the study evaluated outcomes considered relevant such as death, cerebral edema, and seizures, which were defined a priori. We excluded studies in which the cause for dehydration was diarrhea as most children with diarrhea have hypotonic (and hyponatremic) dehydration and the focus of the review was hypernatremic dehydration related to inadequate breastfeeding. Renal and tubular function matures after birth, and this maturation is different depending on the gestational age, therefore we excluded preterm neonates or infants beyond the neonatal period that could be a potential confounder to the results.

We anticipated that there would be a small number of RCTs meeting our inclusion criteria. Therefore, if fewer than 5 RCT were identified, the following criteria were applied: open-label trials, nonrandomized controlled trials, or prospective and retrospective case series (≥5 patients) evaluating relevant outcomes.

Selection of articles was made by 2 independent researchers (A.R.B. and A.D.D.), who evaluated the abstracts identified by the research according to the eligibility criteria. The search was reviewed by a third investigator (C.G.C.) who compared the decisions and solved divergences.

Data Extraction {#sec2_3}
---------------

Data were abstracted independently by 2 reviewers (A.R.B. and A.D.D.). Information regarding the way of administering the treatment \[intravenous (i.v.) or oral\], type of fluid used for treatment, rates of complications and outcomes, as well as rate of SNa reduction were collected. Divergences were solved by consensus or, when needed, by the intervention of a third investigator (C.G.C.). When full text was unavailable, contact with the corresponding author was made in order to obtain the paper. Every selected article was evaluated according to the risk of bias. In order to assess the risk of bias, the methodological quality of the included articles was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group system \[[@B17], [@B18], [@B19]\]. This tool classifies the quality of outcomes as high, moderate, low, and very low \[[@B20]\] using the risk of bias, inconsistency, indirectness, and imprecision as criteria.

Results {#sec1_4}
=======

The searches yielded 540 results in MEDLINE/PubMed, 18 in LILACS, 472 in EMBASE, 1 in Clinical Trials, and 13 in the Cochrane Library. A total of 771 articles had their title and abstracts reviewed by 2 independent reviewers. Of those, 64 were considered eligible for full-text review and 9 articles met the inclusion criteria and were included by consensus (Fig. [1](#F1){ref-type="fig"}). There were no systematic reviews focusing on specifics of treatment and its outcomes and no randomized clinical trials. There were 7 retrospective \[[@B10], [@B21], [@B22], [@B23], [@B24], [@B25]\] and 2 prospective studies \[[@B26], [@B27]\] with ≥5 patients included. Only 2 articles performed direct comparisons regarding different treatments \[[@B10], [@B22]\] (Table [1](#T1){ref-type="table"}), while the remaining studies described types of treatment and outcomes and were kept in the review for descriptive purposes only (Table [2](#T2){ref-type="table"}). One article was a case series of neonates with severe hypernatremia treated with peritoneal dialysis (PD), and we decided to keep it in the review due to its data regarding outcomes of this specific therapy \[[@B25]\]. Three articles included late preterm infants \[[@B22], [@B26], [@B28]\] and we also decided to keep it in the review as these sample included otherwise healthy neonates whose only likely predisposing factor related to hypernatremic dehydration was inadequate breastfeeding. These infants had a birth weight \>2,000 g and were not admitted for other issues related to prematurity.

The studies included a minimum of 5 to a maximum of 149 patients, totalizing 455 patients among the 9 selected studies. There were 208 (45.7%) males, 133 (29.2%) females, and 114 (25%) patients were not classified according to sex. Gestational age ranged from 35 to 42 weeks, birth weight ranged from 2,100 to 5,000 g, and age at diagnosis/admission ranged from 1 to 27 days. The percentage of weight loss ranged from 1 to 35.2%, and serum creatinine and blood urea nitrogen at admission were described from 0.22 to 8 and from 4 to 263 mg/dL, respectively. Symptoms at admission were described as jaundice in 182 (40%) and fever in 183 (40.2%). Other presenting symptoms included weight loss, poor feeding, irritability, restlessness, lethargy, decreased urine output, constipation, vomiting, and seizures.

The study by Bolat et al. \[[@B10]\] was the most detailed regarding treatment, rate of correction of SNa, and outcomes. It consisted of a retrospective analysis and patients were analyzed according to 3 ranges of SNa: groups 1 and 2 (both data described in Table [1](#T1){ref-type="table"}), and group 3 (*n* = 3; SNa between 171-189 mEq/L). Adverse effects were more prevalent when the rate of correction exceeded 0.5 mEq/L/h. Patients in group 3 were treated with bolus of 0.9% saline due to hypovolemic shock and further management included 0.6% saline that was further changed to 0.9% saline due to a drastic decrease of SNa \[[@B10]\]. Logistic regression analysis was performed to analyze independent risk factors for seizures and death: SNa \>160 mEq/L at admission and rate of correction \>0.5 mEq/L/h had an odds ratio of 1.9 and 4.3, respectively.

Erdemir et al. \[[@B22]\] aimed at comparing oral and i.v. rehydration through a retrospective study. Data were analyzed according to the treatment that was instituted: 44 (58.6%) treated with breast milk and/or oral formula and 31 (41.4%) treated with i.v. fluid (4/5 10% dextrose + 1/5 normal saline). There was a significant difference in the rate of correction between both groups at 12 and 24 h. For instance, at 12 h, 93.5% of the patients in the i.v. fluids group had what it was considered a nonsafe drop in SNa (\>0.5 mEq/L/h) compared to 56.8% in the oral therapy group. When considering only patients with higher SNa (\>155 mEq/L), all patients treated with i.v. fluids had a nonsafe drop when compared to only 30.7% of patients in the oral therapy group at 24 h. Only 1 patient (i.v. fluid group) developed seizures and cerebral edema. He had a 12mEq/L drop in SNa at 12 h. No further adverse effects of treatment were described and there was no follow-up for neurodevelopmental evaluation \[[@B22]\].

In the study by Bilgin et al. \[[@B21]\], there was no thorough description of the treatment used, stated only as oral rehydration or i.v. fluid according to the severity. Seven (4.7%) patients developed seizures within 24 h of treatment and 5 patients (3.3%) showed signs of cerebral edema on computed tomography (CT) evaluation. The rate of correction of hypernatremia was not specified \[[@B21]\]. In a retrospective study by Ozdogan et al. \[[@B24]\], 1 patient presented seizures during the rehydration phase (sodium at admission was 188 mEq/L), but there was no description of the rate of SNa drop or the treatment that was used. Patients were treated with fluid bolus NaCl 0.9% and oral feeds or free water for 48-72 h as well as saline boluses. Compared outcomes after treatment were not described \[[@B24]\].

A case series by Ng et al. \[[@B23]\] described 4 patients treated with breast milk and artificial formula supplementation and 1 patient treated with additional i.v. fluids, without description of the characteristics of the fluid. There were no complications in this sample, which could be attributed to the relatively low level of hypernatremia and the more conservative treatment used.

The study by Peker et al. \[[@B28]\] included 10 newborns (1 preterm, 60% of small for gestational age). Fluid with a sodium concentration of 75-100 mEq/L was administered to 4 neonates and it took more than 72 h to achieve SNa concentrations lower than 150 mEq/L. In 6 cases, after the calculation of maintenance and lost fluid, 5% dextrose and 0.2% NaCl solutions were administered. In this group, normal SNa was reached earlier, with a mean period of 48 h. Two of the hypernatremic newborns died during the study (due to meningitis and kernicterus) \[[@B28]\].

A prospective nonrandomized study conducted by Yaseen et al. \[[@B27]\] included 10 patients (35%) receiving oral rehydration, 11 patients (38%) receiving i.v. rehydration, described only as hypotonic, and 8 (28%) receiving both oral and i.v. rehydration. There was a description of fast rehydration with hypotonic fluids causing seizures and coma in 1 patient, and head CT scan showed signs of brain edema \[[@B27]\].

A prospective population-based surveillance study by Oddie et al. \[[@B26]\] described i.v. bolus infusions administered in 14 patients while 31 had ongoing maintenance fluids. There were no adverse effects related to treatment and the authors described a mean drop of 12.7 mEq/L in 24 h of SNa \[[@B26]\].

Yildiz et al. \[[@B25]\] reviewed the medical records of 15 neonates with acute kidney injury and hypernatremic dehydration due to inadequate breast milk intake, who were treated with acute PD (mean duration: 6.36 days). Significant comorbidities were present in 12 infants, and 4 did not survive. All patients were treated initially with isotonic saline solution delivered twice intravenously at a dose of 10-20 mL/kg over 1 h. The decision to begin dialysis was made if, after at least 12 h, conservative management failed to control fluid and electrolyte balance. SNa declined to 160.8 ± 6.7 mg/dL (range: 152-170) at the end of 24 h and to 152 ± 7.1 mg/dL (range: 142-163) after 48 h, lower than 15 mEq/L per day.

Discussion {#sec1_5}
==========

Hypernatremic dehydration is a potentially serious complication of breastfeeding due to inadequate lactation \[[@B4]\]. A large number of retrospective studies have highlighted the importance of recognizing this diagnosis, focusing mainly on the description of clinical signs and symptoms at presentation and risk factors \[[@B2], [@B8], [@B11], [@B29], [@B30], [@B31]\]. However, this systematic review showed that there is a scarcity of good quality studies about the treatment of this condition. There is no randomized clinical trial focusing on the treatment of hypernatremia in term neonates. Only 2 retrospective studies provided some comparison among different treatment strategies and a more thorough evaluation regarding the rate of correction of SNa \[[@B10], [@B22]\], whereas the remaining studies provided descriptions of treatment options and outcomes without details of which solution was used \[[@B21], [@B23], [@B24], [@B25], [@B26], [@B27], [@B28]\].

The proposal of this systematic review was to critically assess the available literature on hypernatremic dehydration in term neonates, seeking to establish the best available intervention and its efficacy and safety. The studies investigated were very heterogeneous and included small numbers of patients with poor description of outcomes and clinical manifestations. Despite the limitations, it sought to critically evaluate the best available evidence. Among the selected studies, there was a great disparity in the outcomes used by the authors, which included predominantly limited reporting of results, which affected the comparison between different papers and thus not obtaining sufficient data to perform meta-analysis of any variable. Therefore, quantitative assessment of heterogeneity of studies as well as assessment of their risk of bias was not performed. This intrinsic limitation arises from the great variability of studies performed and available for review. For the above mentioned reasons, according to GRADE system, the quality of the included studies is low (2 plus, ++).

Three studies included late preterm neonates (\>35 weeks) \[[@B22], [@B26], [@B28]\], but we kept them in the review as a way of preserving a greater number of patients. Although it was not the focus of this study, it is important to acknowledge that late preterm neonates are also subject to hypernatremia dehydration due to insufficient lactation and that there might be interesting differences related to gestational age particularities of renal function maturity \[[@B32], [@B33]\]. Due to these complicated patterns of renal maturation and other possible confounders in the preterm population, we restricted the review solely to term neonates.

Hypernatremia leads to an efflux of fluid from the intracellular to the extracellular compartment, with transient cell shrinkage and cerebral volume decrease \[[@B34]\]. When chronically installed (more than 1--3 days), there is an increased production of idiogenic osmoles that help restore brain volume \[[@B35]\]. Rapid correction of hypernatremia or administration of excessively hypotonic fluids may lead to brain edema due to the brain\'s inability to remove the idiogenic osmoles \[[@B34], [@B35]\] (Fig. [2](#F2){ref-type="fig"}).

The main stem of treatment consists of increasing free water availability to dilute excessive SNa. Moreover, as volume depletion is frequently associated, fluid resuscitation with normal saline or colloid should be instituted prior to the correction of free water deficit \[[@B14], [@B34]\]. Moritz and Ayus \[[@B34]\] acknowledge different strategies according to the cause of hypernatremia: those with sodium overload or renal concentrating defect require more hypotonic fluids than those with volume depletion and normal renal concentrating function. Urinary sodium excretion is inversely related to gestational age and studies show that tubular function is mature in term neonates \[[@B32], [@B33]\].

Apart from the limitations mentioned above, it appears that neonates with more severe hypernatremia are the ones at greater risk of severe adverse effects of treatment. Still, the degree of hypernatremia itself is not the sole predictor of adverse outcomes. The rate of SNa drop plays a major role. In the study by Bolat et al. \[[@B10]\], a rate of SNa correction beyond 0.5 mEq/L/h was significantly associated with adverse outcomes, with an impressive odds ratio of 4.3 for death and neonatal seizures. In Erdemir et al.\'s \[[@B22]\] study, a rate of correction beyond 0.5 mEq/L/h was more prevalent in the group treated with i.v. fluids. Yaseen et al.\'s \[[@B27]\] sample of patients included newborns with a SNa as high as 196 mEq/L; however, adverse effects were observed in a patient with a SNa of 160 mEq/L, described as having received fast rehydration with glucose and hypotonic fluids. Although rate thresholds have been traditionally described as 0.5-1 mEq/L/h \[[@B13], [@B14]\], there is not enough evidence to support these recommendations. For instance, in this review, we were not able to gather enough data to attempt to construct a ROC curve to determine an optimal rate threshold.

The estimation of free water deficit, which takes into consideration lean body weight and desired SNa, is an interesting strategy to calculate the amount of fluid necessary to correct the SNa \[[@B14]\]. The tonicity of the fluid used to correct the water deficit should be tailored according to the severity of hypernatremia. Bell et al. \[[@B36]\] recommend a sodium drop of less than 15 mEq/L during a 24-hour period, correcting the free water deficit with hypotonic fluid. Although there is no consensus about the optimal rate of SNa drop in hypernatremic term neonates, it is clear from the studies presented that a slower correction appears to be safer. In fact, a close monitoring of SNa should be strongly encouraged.

Conclusions and Future Directions {#sec1_6}
=================================

Taken the pathophysiological cause of hypernatremia in term neonates and the increased incidence of adverse outcomes in patients with rapid correction of SNa, it seems that a more conservative approach, with fluids that are mildly hypotonic, may be more appropriate in those with more severe hypernatremia. Furthermore, careful and frequent monitoring of SNa during the rehydration phase is imperative. We suggest that adjustments of fluid therapy should be carried out during treatment to avoid SNa drops greater than 0.5 mEq/L/h. Questions as to when increasing enteral feeds is not enough and parenteral fluids are indicated remain unanswered. In this scenario, we strongly recommend that large prospective studies and randomized clinical trials should be done in order to clarify these questions. In addition, as highlighted by some of the severe adverse outcomes related to the condition and its treatment, the prevention of hypernatremic dehydration associated with inadequate breastfeeding is judicious. Lactation support and education, as well as careful follow-up and weight measurements, are likely to be helpful not only as preventative measures but also in early identification of vulnerable infants.
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![**a** Similar tonicity between the plasma and the cell. **b** Acute hypernatremia: efflux of sodium and water. **c** Chronic hypernatremia: idiogenic osmoles enter into the cell to maintain osmolarity and cell volume. **d** Rapid rehydration: relative inability to exclude the idiogenic osmoles and influx of water leads to edema.](bmh-0002-0001-g02){#F2}

###### 

Summary of findings from retrospective studies that compared different treatments for hypernatremia in newborns

                                    Bolat \[[@B10]\]   Erdemir \[[@B22]\]                                      
  --------------------------------- ------------------ -------------------- ---------- -------- -------------- -------------------------
  Participants                      81                                                          75             
                                                                                                               
  Gestational age, weeks            ≥37                                                         ≥35            
                                                                                                               
  Mean age at admission± SD, days   5                                       8                   4.8±3.0        3.8±2.2
   Range                            2--17                                   2--21               2--15          1--17
                                                                                                               
  Mean BW±SD, g                     3,450±283                               3470±275            3,390±62       3,265±607
   Range                                                                                        2,700--4,500   2,500--4,400
                                                                                                               
  Mean WL±SD, %                     16.8±4.4                                20.4±6.4            7.5±6.6        5.0±3.3
   Range                                                                                        1--30          1--18
                                                                                                               
  Mean serum sodium± SD, mEq/L      156.5±2.6                               164±3.06            153            152
   Range                                                                                        150--168       150--158
                                                                                                               
  Mean serum creatinine, mg/dL      1.25                                    1.58                1.2            1.1
   Range                            0.4--8                                  0.5--4.5            0.3--2.4       0.7--2.0
                                                                                                               
  Mean serum BUN, mg/dL             40                                      95                  57             41
   Range                            4--263                                  18--178             27--175        17--107
                                                                                                               
  Treatment                                                                                     i.v. fluids    breast milk and formula
                                                                                                               
  Bolus NaCl 0.9%                   1 (9)                                   7 (30.4)                           
                                                                                                               
  i.v. rehydration, NaCl, %         0.3                                     0.45                               
                                                                                                               
  Rate of correction at 48 h                                                                                   
   ≤0.5 mmol/L/h                    32                                      13                                 
   \>0.5 mmol/L/h                                      23                              10                      
                                                                                                               
  Seizures                          5 (15.6)           7 (30.4)             3 (23)     7 (70)   1 (3.2)        
                                                                                                               
  Brain edema                                          2 (8.7)                         3 (30)   1 (3.2)        
                                                                                                               
  Death                             1 (3.1)            1 (4.3)              2 (15.3)   2 (20)                  

Values are numbers with percentages in parentheses, except where otherwise indicated. Data is displayed when available in the article. BW, body weight; WL = weight loss; i.v. = intravenous.

###### 

Summary of findings from articles included in systematic reviews and outcome after treatment of dehydration[^1^](#T2F1){ref-type="table-fn"}

  First author \[Ref.\]   *N*   GA, weeks   Age at admission[^2^](#T2F2){ref-type="table-fn"}, days   Birth weight[^2^](#T2F2){ref-type="table-fn"},g   Weight loss[^2^](#T2F2){ref-type="table-fn"}, %   Serum sodium[^2^](#T2F2){ref-type="table-fn"}, mEq/L   Treatment   Outcome                                      
  ----------------------- ----- ----------- --------------------------------------------------------- ------------------------------------------------- ------------------------------------------------- ------------------------------------------------------ ----------- --------- ----- ---------- ------ ---------- ---
  Bilgin \[[@B21]\]       149   term        4.5±3.8                                                   3,325±558                                         13±6.3                                            155                                                    yes         yes       yes   7 (4.7%)   32.9   5 (3.3%)   0
   Range                                    1--27                                                     2,400--5,000                                      3.3--35.2                                         150--190                                                                                                        
                                                                                                                                                                                                                                                                                                                          
  Ozdogan \[[@B24]\]      29    term        5.6                                                       3,350                                             15.5                                              160.7                                                  yes                   yes   1          2      0          0
   Range                                    2--12                                                     2,100--4,400                                      6--29                                             150--188                                                                                                        
                                                                                                                                                                                                                                                                                                                          
  Ng \[[@B23]\]           5     term        4.8±1.64                                                  3,127±370                                                                                           152.8±1.3                                              yes         yes       yes   0          0      0          0
   Range                                    3--6                                                      2,635--3,510                                      11--14                                            151--154                                                                                                        
                                                                                                                                                                                                                                                                                                                          
  Peker \[[@B28]\]        10                6.5±2.4                                                                                                                                                       169.4±7.8                                              yes                         2          4      0          2
   Range                                    3--10                                                                                                                                                         160.5--185                                                                                                      
                                                                                                                                                                                                                                                                                                                          
  Yaseen \[[@B27]\]       29    \>37        4.9±2.5                                                   3,084±435                                         16.5±4.1                                          155±9.5                                                yes         yes       yes   1          0      1          0
   Range                                    2--13                                                                                                       12--29                                            150--196                                                                                                        
                                                                                                                                                                                                                                                                                                                          
  Oddie \[[@B26]\]        62    \>33        6                                                         3,467±537                                         19.5                                              164                                                    yes                         0          0      0          0
   Range                                    3--17                                                                                                       8.9--30.9                                         160--187                                                                                                        
                                                                                                                                                                                                                                                                                                                          
  Yildiz \[[@B25]\]       15    term                                                                  3,096.7±143                                       11.4±1.7                                          169.2±6.5                                              PD                          0          15     0          4
   Range                                    4--27                                                                                                                                                         158--180                                                                                                        

Data shown in Table [1](#T1){ref-type="table"} is not displayed.

Values are given as mean±SD. Data is displayed when available in the article. AKI, acute kidney injury; GA, gestational age; i.v., intravenous; PD, peritoneal disease.

[^1]: A.R.B. and A.D.D. contributed equally to this work.
